Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 HER2 status and benefit from adjuvant trastuzumab in breast cancer.

× No keyword cloud information.

161 in total

1. NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.

Authors: Alan P Venook; Maria E Arcila; Al B Benson; Donald A Berry; David Ross Camidge; Robert W Carlson; Toni K Choueiri; Valerie Guild; Gregory P Kalemkerian; Razelle Kurzrock; Christine M Lovly; Amy E McKee; Robert J Morgan; Anthony J Olszanski; Mary W Redman; Vered Stearns; Joan McClure; Marian L Birkeland
Journal: J Natl Compr Canc Netw Date: 2014-11 Impact factor: 11.908

2. A mammary stem cell population identified and characterized in late embryogenesis reveals similarities to human breast cancer.

Authors: Benjamin T Spike; Dannielle D Engle; Jennifer C Lin; Samantha K Cheung; Justin La; Geoffrey M Wahl
Journal: Cell Stem Cell Date: 2012-02-03 Impact factor: 24.633

Review 3. Targeting breast cancer stem cells.

Authors: Suling Liu; Max S Wicha
Journal: J Clin Oncol Date: 2010-05-24 Impact factor: 44.544

4. Long-term cultures of stem/progenitor cells from lobular and ductal breast carcinomas under non-adherent conditions.

Authors: Agostina Nardone; Sara Corvigno; Annalisa Brescia; Daniel D'Andrea; Gennaro Limite; Bianca Maria Veneziani
Journal: Cytotechnology Date: 2010-12-28 Impact factor: 2.058

5. Breast cancer: updated guideline recommendations for HER2 testing.

Authors: Emad A Rakha; Ian O Ellis
Journal: Nat Rev Clin Oncol Date: 2013-12-10 Impact factor: 66.675

Review 6. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.

Authors: Carlos L Arteaga; Jeffrey A Engelman
Journal: Cancer Cell Date: 2014-03-17 Impact factor: 31.743

7. Chromatin modifications sequentially enhance ErbB2 expression in ErbB2-positive breast cancers.

Authors: Sathish Kumar Mungamuri; William Murk; Luca Grumolato; Emily Bernstein; Stuart A Aaronson
Journal: Cell Rep Date: 2013-10-10 Impact factor: 9.423

Review 8. Biomarker enrichment strategies: matching trial design to biomarker credentials.

Authors: Boris Freidlin; Edward L Korn
Journal: Nat Rev Clin Oncol Date: 2013-11-26 Impact factor: 66.675

Review 9. Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer.

Authors: Zeynep Eroglu; Tomoko Tagawa; George Somlo
Journal: Oncologist Date: 2014-01-16

10. Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).

Authors: Begoña Martin-Castillo; Cristina Oliveras-Ferraros; Alejandro Vazquez-Martin; Silvia Cufí; José Manuel Moreno; Bruna Corominas-Faja; Ander Urruticoechea; Ángel G Martín; Eugeni López-Bonet; Javier A Menendez
Journal: Cell Cycle Date: 2012-01-15 Impact factor: 4.534